Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPPEREIRA, F. A.MATTAR, R.FACINCANI, I.DEFINO, H. L. A.RAMALHO, L. N. Z.JORGETTI, V.VOLPON, J. B.PAULA, F. J. A. de2013-07-302013-07-302012BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.45, n.12, p.1255-1261, 20120100-879Xhttps://observatorio.fm.usp.br/handle/OPI/1303Osteoporosis is a major complication of chronic cholestatic liver disease (CCLD). We evaluated the efficacy of using disodium pamidronate (1.0 mg/kg body weight) for the prevention (Pr) or treatment (Tr) of cholestasis-induced osteoporosis in male Wistar rats: sham-operated (Sham = 12); bile duct-ligated (Bi = 15); bile duct-ligated animals previously treated with pamidronate before and 1 month after surgery (Pr = 9); bile duct-ligated animals treated with pamidronate 1 month after surgery (Tr = 9). Rats were sacrificed 8 weeks after surgery. Immunohistochemical expression of IGF-I and GH receptor was determined in the proximal growth plate cartilage of the left tibia. Histomorphometric analysis was performed in the right tibia and the right femur was used for biomechanical analysis. Bone material volume over tissue volume (BV/TV) was significantly affected by CCLD (Sham = 18.1 +/- 3.2 vs Bi = 10.6 +/- 2.2%) and pamidronate successfully increased bone volume. However, pamidronate administered in a preventive regimen presented no additional benefit on bone volume compared to secondary treatment (BV/TV: Pr = 39.4 +/- 12.0; Tr = 41.2 +/- 12.7%). Moreover, the force on the momentum of fracture was significantly reduced in Pr rats (Sham = 116.6 +/- 23.0; Bi = 94.6 +/- 33.8; Pr = 82.9 +/- 22.8; Tr = 92.5 +/- 29.5 N; P < 0.05, Sham vs Pr). Thus, CCLD had a significant impact on bone histomorphometric parameters and pamidronate was highly effective in increasing bone mass in CCLD; however, preventive therapy with pamidronate has no advantage regarding bone fragility.engopenAccessOsteoporosis pathogenesisGrowth factorsBiomechanicsAnimal modelsPamidronatemetabolic bone-diseasepostmenopausal osteoporosishepatic osteodystrophyvertebral fracturesrandomized-trialcirrhosisbisphosphonatewomenrisedronatechildrenarticleCopyright ASSOC BRAS DIVULG CIENTIFICA10.1590/S0100-879X2012007500143BiologyMedicine, Research & Experimental